Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0345904 (
liver cancer
)
15,188
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
BTG2/
TIS21
/PC3 (B cell translocation gene 2) has been known as a p53 target gene and functions as a tumor suppressor in carcinogenesis of thymus, prostate, kidney, and liver. Although it has been known that the expression of BTG2/
TIS21
/PC3 is induced during chemotherapy-mediated apoptosis in cancer cells, a role of BTG2/
TIS21
/PC3 in cell death remains to be elucidated. In this study, the mechanism and role of BTG2 involved in the enhancement of doxorubicin (DOXO)-induced cell death were examined. Treatment of HeLa cells with DOXO revealed apoptotic phenomena, such as chromatin condensation and cleavage of poly(ADP-ribose) polymerase and lamin A/C with concomitant increase of BTG2/
TIS21
/PC3 expression. Employing infections of Ad-
TIS21
virus and lentivirus with short hairpin RNA to BTG2, the effect of BTG2/
TIS21
/PC3 on the DOXO-induced apoptosis of HeLa cells and
liver cancer
cells was evaluated. Not only short hairpin RNA-BTG2 but also N-acetyl-L-cysteine significantly reduced the DOXO-induced HeLa cell death and generation of H2O2. Moreover, forced expression of BTG2/
TIS21
/PC3 using adenoviral vector augmented DOXO-induced cancer cell death concomitantly with increase of manganese-superoxide dismutase but not catalase, CuZnSOD, and glutathione peroxidase 1. The increased apoptosis by forced expression of BTG2/
TIS21
/PC3 could be inhibited by N-acetyl-L-cysteine and polyethylene glycol-catalase. These results therefore suggest that BTG2/
TIS21
/PC3 works as an enhancer of DOXO-induced cell death via accumulation of H2O2 by up-regulating manganese-superoxide dismutase without any other antioxidant enzymes. In summary, BTG2/
TIS21
/PC3 enhances cancer cell death by accumulating H2O2 via imbalance of the antioxidant enzymes in response to chemotherapy.
...
PMID:B cell translocation gene 2 enhances susceptibility of HeLa cells to doxorubicin-induced oxidative damage. 1884 Jun 9
B-cell translocation gene 2
(
BTG2
) proteins have been reported to be putative tumor suppressors in various cancer types. The present study first assessed
BTG2
expression in 44 human
liver cancer
tissue specimens, then investigated
BTG2
expression in the regulation of hepatocellular carcinoma (HCC) cell apoptosis with or without radiotherapy
in vitro
and
in vivo
. The results revealed that
BTG2
protein expression was significantly reduced in HCC tissues, and associated with better survival for HCC patients (P=0.05).
BTG2
overexpression also sensitized Huh7 cells to radiation-induced apoptosis
in vitro
and in a nude mouse model, although restoration of
BTG2
expression
per se
did not affect the viability and apoptosis of HCC cells. Future studies would confirm the role of
BTG2
in hepatoma, and further develop
BTG2
as a therapeutic strategy for controlling HCC.
...
PMID:Expression of B-cell translocation gene 2 is associated with favorable prognosis in hepatocellular carcinoma patients and sensitizes irradiation-induced hepatocellular carcinoma cell apoptosis
in vitro
and in nude mice. 2845 5